Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
ARQT - Arcutis Biotherapeutics, Inc.
Market Cap 629.58M P/E - EPS this Y 49.70% Ern Qtrly Grth -
Income -217.42M Forward P/E -2.76 EPS next Y 36.30% 50D Avg Chg 8.00%
Sales 106.39M PEG -0.54 EPS past 5Y - 200D Avg Chg -25.00%
Dividend N/A Price/Book 4.50 EPS next 5Y 9.80% 52W High Chg -63.00%
Recommedations 2.10 Quick Ratio 9.32 Shares Outstanding 115.76M 52W Low Chg 41.00%
Insider Own 2.24% ROA -28.62% Shares Float 89.26M Beta 1.18
Inst Own 109.88% ROE -119.24% Shares Shorted/Prior 22.66M/26.02M Price 10.25
Gross Margin 92.99% Profit Margin -204.36% Avg. Volume 1,262,433 Target Price 19.17
Oper. Margin -63.79% Earnings Date Aug 6 Volume 568,776 Change -3.03%
Healthcare | Biotechnology | United States
About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Arcutis Biotherapeutics, Inc. News
07/23/24 Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and Over
07/22/24 Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL
07/19/24 Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
07/17/24 Arcutis (ARQT) Stock Rises 31% in the Past Month: Here's Why
07/16/24 Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
07/15/24 Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
07/12/24 Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
07/12/24 Pacira (PCRX) Rises on Proposed Exparel Reimbursement Plan
07/12/24 Inovio (INO) Up as Lead Drug Gets Innovative Medicine Tag in UK
07/10/24 Arcutis bags FDA approval for atopic dermatitis cream after delay
07/10/24 Indivior (INDV) Down on Dropping Schizophrenia Drug, Cuts '24 View
07/10/24 FDA Approves Expanded Use Of Arcutis Biotherapeutics' Eczema Drug For Patients As Young As 6 Years
07/10/24 AbbVie names new R&D head; Arcutis eczema cream approved
07/09/24 FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
07/09/24 Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic Dermatitis
07/03/24 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/02/24 Cheap Stocks To Buy: This Microcap Gold Stock Breaks Out
07/01/24 FDA Rejects Rocket's (RCKT) Gene Therapy BLA for Rare Disease
10:03 AM FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma
06/26/24 AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
ARQT Chatroom

User Image ZManicItalian Posted - 9 hours ago

$ARQT chart update. Let's break that top blue line 👹

User Image zawojak Posted - 9 hours ago

$ARQT at least we are over $10 on Friday AH📈👋

User Image ZManicItalian Posted - 12 hours ago

$ARQT 👀 "zoryve" via Google trends. Sales might be taking another leg up right now 🤔 🍻🐂

User Image Doozio Posted - 13 hours ago

$ARQT whut to pump again next in 🧠⏰♾️. Barring a faatch 💣. Obviously

User Image Rhody27 Posted - 13 hours ago

$ARQT the MMs have this pinned. They might let it rally into the close. We'll see.

User Image zawojak Posted - 13 hours ago

$ARQT calm before BO announcement??

User Image MarcusEpi Posted - 13 hours ago

$ARQT making zero progress in AD

User Image zawojak Posted - 1 day ago

$ARQT deja vu past few weeks ...

User Image PsychoNut710 Posted - 1 day ago

$ARQT I just hope for 11s tom or Friday

User Image 85Thebrit Posted - 1 day ago

$ARQT swings and roundabouts, just the typical dollar holla for y'all 😅😘

User Image GoodOlJR Posted - 1 day ago

$ARQT can all you Jabroni’s shut up now? This things BETA makes it a force to move either direction. So chill your tits

User Image ElleFuller Posted - 1 day ago

$ARQT we did it - we broke $10.50🥳🥳🥳🥳🥳🥳🥳

User Image Dilly_Poppins Posted - 1 day ago

$ARQT feels squeezy

User Image ElleFuller Posted - 1 day ago

$ARQT Nice movement - pattern's been a bit consistent this week. Perhaps we break 10.50?

User Image jacckkmm Posted - 1 day ago

$ASTS and $arqt. Today’s daily double. Hello money!!! Love it!

User Image GoodOlJR Posted - 2 days ago

$ARQT Viking therapeutics earnings should be a nice help to the sector & small caps. Russell 2000 is about to put the team on its back for the short term.

User Image frontiere Posted - 2 days ago

+ fwiw listed broad comps to $ABIO ARCA / $ORKA Oruka : $ROIV Roivant $INCY Incyte $ARQT Arcutis $VYNE VYNE etc Once ABIO post merger float released will be a big short opp if MCap hangs around current implied values. 🚩 https://stocktwits.com/frontiere/message/545620712

User Image Dilly_Poppins Posted - 2 days ago

$ARQT for whoever needs to hear this; the majority of the stock market had a year’s worth of gains in the first three months of the year (with exception of mag 7 and freinds). That was a gift and if you didn’t capitalize on it and are now chasing gains into a seasonally low time for stocks ahead of an election you need to reassess your expectations. Big tech is in a correction so the major averages will be under pressure for a little while. The rotation into small caps and bio might hold up so this could be our saving grace. Like anyone else who is long I also want this above $15 where it belongs but we are doing OKAY. Technicals are stable and fundamentals rock. Let this puppy cook

User Image Dilly_Poppins Posted - 2 days ago

$ARQT YTD ARQT up 230% XBI up 12%

User Image khanso Posted - 2 days ago

$ARQT xbi is up…whats with this stock!

User Image Rhody27 Posted - 2 days ago

$ARQT well this sucks

User Image zawojak Posted - 2 days ago

$ARQT Crossing moving average

User Image PsychoNut710 Posted - 3 days ago

$ARQT 39900 shares at 10.25

User Image Dilly_Poppins Posted - 3 days ago

$ARQT bull flag

User Image JOEYD05 Posted - 3 days ago

$ARQT TV commercials are coming….🚀🚀🚀🚀🚀

User Image jacckkmm Posted - 3 days ago

$ARQT I love this!!!. Boom! Updated: 23-Jul-24 08:06 ET ARQT: Arcutis Biotherapeutics announces the submission of a supplemental New Drug Application for ZORYVE foam 0.3%, a once-daily, next generation phosphodiesterase-4 inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis.

User Image briefingcom Posted - 3 days ago

$ARQT: Arcutis Biotherapeutics announces the submission of a supplemental New Drug Application for ZORYVE foam 0.3%, a once-daily, next generation phosphodiesterase-4 inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20240723080647ARQT&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

User Image zawojak Posted - 3 days ago

$ARQT unbelievably shorted :/

User Image Carl83 Posted - 3 days ago

$ARQT C'mon, fly!

User Image Night_Owl_Biotech Posted - 3 days ago

A comparison of $PHAT 's valuation (yesterday morning) v $PRVB & $VIE M&A valuation as they had like 9-year revenue projections. We added a flux to $ARQT valuation as a multiple of cumulative 9-year sales. Just a reminder this was posted yesterday morning. $XBI As always this is not investment advice. https://youtu.be/0lvMT0GhAKE

Analyst Ratings
Needham Buy Jul 10, 24
Needham Buy May 15, 24
Mizuho Buy May 15, 24
Needham Buy Apr 12, 24
Goldman Sachs Neutral Feb 28, 24
Mizuho Buy Feb 28, 24
Needham Buy Feb 28, 24
Mizuho Buy Feb 23, 24
Mizuho Buy Jan 3, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Burnett Patrick See Remarks See Remarks Jan 02 Sell 3.5408 1,325 4,692 57,032 01/03/24
Watanabe Todd Franklin See Remarks See Remarks May 31 Buy 6.38 1,463 9,334 515,145 12/01/23
Watanabe Todd Franklin See Remarks See Remarks May 31 Option 1.68 59,525 100,002 513,682 12/01/23
Matsuda Masaru See Remark See Remark Nov 18 Sell 1.98 1,850 3,663 46,634 11/21/23
Burnett Patrick See Remarks See Remarks Aug 18 Sell 7.05 1,605 11,315 58,357 08/22/23
Matsuda Masaru See Remark See Remark May 27 Sell 7.8 1,830 14,274 42,146 06/02/23
Welgus Howard G. Director Director Apr 17 Sell 13.97 8,500 118,745 165,825 04/18/23
Welgus Howard G. Director Director Apr 17 Option 1.68 8,500 14,280 174,325 04/18/23
Moore Matthew Richard See Remarks See Remarks Mar 02 Sell 16.17 1,610 26,034 11,690 03/06/23
Matsuda Masaru See Remarks See Remarks Mar 02 Sell 16.17 1,434 23,188 18,101 03/06/23
Burnett Patrick See Remarks See Remarks Mar 02 Sell 16.17 1,751 28,314 39,813 03/06/23
Watanabe Todd Franklin See Remarks See Remarks Feb 28 Sell 16.17 7,815 126,369 369,092 03/02/23
Burrows Scott L Chief Financial Offi.. Chief Financial Officer Feb 28 Sell 16.17 1,850 29,915 38,406 03/02/23
Lock Kenneth A. Chief Commercial Off.. Chief Commercial Officer Feb 28 Sell 16.17 2,368 38,291 43,260 03/02/23
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Feb 28 Sell 16.17 2,005 32,421 254,644 03/02/23
Welgus Howard G. Director Director Feb 15 Sell 16.98 8,500 144,330 165,825 02/21/23
Welgus Howard G. Director Director Feb 15 Option 1.68 8,500 14,280 174,325 02/21/23
Watanabe Todd Franklin See Remarks See Remarks Feb 13 Sell 17.02 1,000 17,020 376,907 02/15/23
Welgus Howard G. Director Director Jan 17 Sell 13.72 8,500 116,620 165,825 01/18/23
Welgus Howard G. Director Director Jan 17 Option 1.68 8,500 14,280 174,325 01/18/23
Burrows Scott L Chief Financial Offi.. Chief Financial Officer Sep 16 Option 1.6806 5,000 8,403 40,256 09/20/22
Watanabe Todd Franklin President and CEO President and CEO Sep 07 Sell 21.51 1,000 21,510 381,907 09/09/22
Welgus Howard G. Director Director Aug 15 Sell 24.7981 6,000 148,789 174,208 08/17/22
Watanabe Todd Franklin President and CEO President and CEO Aug 05 Option 1.68 2,500 4,200 654,371 08/09/22
Watanabe Todd Franklin President and CEO President and CEO Aug 05 Sell 24.74 2,500 61,850 651,871 08/09/22
Frazier Life Sciences VIII, L.... 10% Owner 10% Owner Aug 05 Buy 20.00 250,000 5,000,000 8,684,232 08/09/22
Turney Patricia A. SVP, Operations SVP, Operations Mar 23 Option 6.52 15,331 99,958 46,444 08/04/22
Welgus Howard G. Director Director Jul 18 Sell 24.3956 6,000 146,374 180,208 07/18/22
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Jul 08 Sell 25.4144 2,197 55,835 256,649 07/12/22
Watanabe Todd Franklin President and CEO President and CEO Jul 08 Option 1.68 7,087 11,906 658,958 07/12/22
Watanabe Todd Franklin President and CEO President and CEO Jul 08 Sell 25.28 13,500 341,280 651,871 07/12/22
Watanabe Todd Franklin President and CEO President and CEO Jul 06 Sell 22.07 1,000 22,070 658,284 07/07/22
Watanabe Todd Franklin President and CEO President and CEO May 05 Sell 21.76 1,000 21,760 658,667 05/05/22
Welgus Howard G. Director Director May 02 Option 1.13 2,500 2,825 184,396 05/03/22
Welgus Howard G. Director Director May 02 Sell 20.44 2,500 51,100 181,896 05/03/22
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Apr 21 Sell 20.4243 2,197 44,872 257,229 04/21/22
ORBIMED ADVISORS LLC 10% Owner 10% Owner Apr 06 Sell 20.69 878,200 18,169,958 451,086 04/08/22
Watanabe Todd Franklin President and CEO President and CEO Apr 05 Sell 21.43 1,000 21,430 659,667 04/05/22
Welgus Howard G. Director Director Apr 01 Option 0.58 7,500 4,350 189,396 04/01/22
Welgus Howard G. Director Director Apr 01 Sell 20.02 7,500 150,150 181,896 04/01/22
Watanabe Todd Franklin President and CEO President and CEO Mar 09 Sell 17.00 300 5,100 660,667 03/11/22
Watanabe Todd Franklin President and CEO President and CEO Mar 03 Option 1.68 700 1,176 661,667 03/07/22
Watanabe Todd Franklin President and CEO President and CEO Mar 03 Sell 16.8 3,259 54,751 660,967 03/07/22
Burnett Patrick See Remarks See Remarks Mar 03 Sell 16.65 1,011 16,833 43,039 03/07/22
Lock Kenneth A. Chief Commercial Off.. Chief Commercial Officer Mar 03 Sell 16.65 1,023 17,033 44,011 03/07/22
Burrows Scott L Chief Financial Offi.. Chief Financial Officer Mar 03 Sell 16.65 303 5,045 35,256 03/07/22
Turney Patricia A. SVP, Operations SVP, Operations Mar 03 Sell 16.65 1,023 17,033 31,113 03/07/22
OSBORNE DAVID W Chief Technical Offi.. Chief Technical Officer Mar 03 Sell 16.65 856 14,252 259,426 03/07/22
Watanabe Todd Franklin President and CEO President and CEO Feb 09 Option 1.68 1,000 1,680 595,779 02/11/22
Watanabe Todd Franklin President and CEO President and CEO Feb 09 Sell 17 1,000 17,000 594,779 02/11/22